[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Argenx Se ADR (ARGX)

Argenx Se ADR (ARGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 64,013,044
  • Shares Outstanding, K 62,561
  • Annual Sales, $ 4,248 M
  • Annual Income, $ 1,292 M
  • EBIT $ 1,602 M
  • EBITDA $ 1,630 M
  • 60-Month Beta 0.46
  • Price/Sales 15.59
  • Price/Cash Flow 49.64
  • Price/Book 7.87

Options Overview Details

View History
  • Implied Volatility 32.89% (-0.02%)
  • Historical Volatility 57.42%
  • IV Percentile 13%
  • IV Rank 30.40%
  • IV High 46.46% on 10/28/25
  • IV Low 26.96% on 08/26/26
  • Expected Move (DTE 20) 57.61 (5.63%)
  • Put/Call Vol Ratio 4.50
  • Today's Volume 176
  • Volume Avg (30-Day) 374
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 7,405
  • Open Int (30-Day) 7,712
  • Expected Range 965.60 to 1,080.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $7.58
  • Number of Estimates 7
  • High Estimate $8.77
  • Low Estimate $6.39
  • Prior Year $5.18
  • Growth Rate Est. (year over year) +46.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
826.45 +23.81%
on 08/03/26
1,061.57 -3.61%
on 08/27/26
+150.98 (+17.31%)
since 07/28/26
3-Month
793.21 +29.00%
on 06/03/26
1,061.57 -3.61%
on 08/27/26
+184.72 (+22.03%)
since 05/28/26
52-Week
661.85 +54.60%
on 03/20/26
1,061.57 -3.61%
on 08/27/26
+319.14 (+45.33%)
since 08/28/25

Most Recent Stories

More News
argenx Completes Acquisition of Forte Biosciences, Inc.

Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx’s immunology pipeline

FBRX : 76.99 (+0.03%)
ARGX : 1,023.21 (-3.37%)
UBS Just Upgraded Argenx Stock. Here's Why.

Argenx shares rally as UBS issues a bullish note. Here’s how high its analyst expects ARGX stock to fly in 2026.

ARGX : 1,023.21 (-3.37%)
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

August 17, 2026, 7:00 AM CET

ARGX : 1,023.21 (-3.37%)
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Forte Biosciences ...

FBRX : 76.99 (+0.03%)
ARGX : 1,023.21 (-3.37%)
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

August 6, 2026 – 7:45 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced that...

FBRX : 76.99 (+0.03%)
ARGX : 1,023.21 (-3.37%)
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026

August 3, 2026 – 22:01 PM CEST

ARGX : 1,023.21 (-3.37%)
The Charts Reveal Significant Price Movement in Forte Biosciences Stock Ahead of Argenx’s Acquisition Announcement

Argenx (ARGX) announced the acquisition of Forte Biosciences (FBRX) at $77 per share on July 27. FBRX saw significant price movement beginning June 29, weeks before the public announcement. Both FBRX and...

FBRX : 76.99 (+0.03%)
ARGX : 1,023.21 (-3.37%)
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Forte Biosciences ...

FBRX : 76.99 (+0.03%)
ARGX : 1,023.21 (-3.37%)
The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today

Forte Biosciences stock soars on a $2.2 billion takeover proposal from Argenx. But is there any further upside left in FBRX shares? Let’s find out!

FBRX : 76.99 (+0.03%)
ARGX : 1,023.21 (-3.37%)
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth ...

FBRX : 76.99 (+0.03%)
ARGX : 1,023.21 (-3.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands.

See More

Key Turning Points

3rd Resistance Point 1,079.01
2nd Resistance Point 1,066.00
1st Resistance Point 1,044.61
Last Price 1,023.21
1st Support Level 1,010.21
2nd Support Level 997.20
3rd Support Level 975.81

See More

52-Week High 1,061.57
Last Price 1,023.21
Fibonacci 61.8% 908.88
Fibonacci 50% 861.71
Fibonacci 38.2% 814.54
52-Week Low 661.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.